Effexor: Insomnia & Night Sweats + Withdrawal & Brain Zaps: Peoples Pharmacy

Paragraph two reads:  “After cutting my dose in
half,
I have had brain zaps (impossible to explain) and
pressure in my ears.”

http://www2.timesdispatch.com/rtd/lifestyles/local_other/article/S-PHAR06_20090902-190006/290023/

Q:I have been taking Effexor XR for two
years. At first I was pleased that it relieved the anxiety, depression and
excessive worrying I had been suffering. Then I began experiencing insomnia and

night sweats and decided to taper off this antidepressant.

After cutting
my dose in half, I have had brain zaps (impossible to explain) and pressure in
my ears.

Answer: Many people find that antidepressants such as Effexor
(venlafaxine), Cymbalta (duloxetine), Lexapro (escitalopram), Paxil (paroxetine)
and Zoloft (sertraline) are helpful for depression. But there can be a dark
side.

Stopping this type of drug can lead to withdrawal symptoms such as
dizziness, headaches, insomnia, anxiety, sweating, visual disturbances and
difficulty concentrating. Many people complain of shocklike sensations in their
head (brainzaps” or “shivers”).

260 total views, 1 views today

Effexor/SSRI Withdrawal: Brain Zaps: Peoples Pharmacy

Paragraph two reads:  “After cutting my dose in half, I have had brain zaps (impossible to explain) and pressure in my ears.”

http://www2.timesdispatch.com/rtd/lifestyles/local_other/article/S-PHAR06_20090902-190006/290023/

Q:I have been taking Effexor XR for two years. At first I was pleased that it relieved the anxiety, depression and excessive worrying I had been suffering. Then I began experiencing insomnia and night sweats and decided to taper off this antidepressant.

After cutting my dose in half, I have had brain zaps (impossible to explain) and pressure in my ears.

Answer: Many people find that antidepressants such as Effexor (venlafaxine), Cymbalta (duloxetine), Lexapro (escitalopram), Paxil (paroxetine) and Zoloft (sertraline) are helpful for depression. But there can be a dark side.

Stopping this type of drug can lead to withdrawal symptoms such as dizziness, headaches, insomnia, anxiety, sweating, visual disturbances and difficulty concentrating. Many people complain of shocklike sensations in their head (brainzaps” or “shivers”).

298 total views, 1 views today

SSRI: 100-500% Increased Risk of Heart Birth Defects If Taken In Early Pregnancy

NOTE FROM Ann Blake-Tracy (www.drugawareness.org): This new study SHOULD stop the Mother’s Act dead in its tracks! The Mother’s Act is designed to medicate pregnant and nursing mothers for depression and we know what they medicate them with – these drugs that they have just shown amazingly damaging effects upon the heart of the fetus!

ANY YOUNG WOMAN WHO INTENDS TO HAVE A FAMILY SHOULD BE WARNED OF THIS POSSIBILITY OF SERIOUS LIFE THREATING BIRTH DEFECTS IN HER OFFSPRING BEFORE EVER BEING STARTED ON AN SSRI ANTIDEPRESSANT!! Marketing these drugs to this age group should be considered criminal when you look at what this study shows to be the risks to the children born to these mothers.

And if you think this does not affect you, think again. You need to see what these children go through (if they survived their mother’s use of these drugs) throughout their lives due to their mother’s use of these drugs! Who do you think ends up paying the bills for the numerous reconstructive surgeries, the lifetime of medications and medical treatment? We do. All of us in higher insurance rates, disability payments, etc., etc., etc.

PLEASE CAREFULLY EXAMINE THE FOLLOWING RESULTS OF THIS STUDY AND SHARE IT WITH EVERYONE YOU KNOW!!! Doing so may spare at least one baby from this horror.

Here is just one small example: http://bigpharmavictim.blogspot.com Manie’s mother was given Paxil and assured it would be okay as so many mothers are told. Her infant son, Manie, was born with Transposition of the Great Arteries and had to have open heart surgery when he was only 8 days old. The surgery lasted 12 hours.
___________________________

Paragraph one reads: “If you take antidepressants such as fluoxetine (marketed as Prozac) early in your pregnancy, you may be doubling the risk that your newborn will be born with a heart defect, according to a new study.”

Paragraph four reads: “Along with fluoxetine, sertraline (marketed as Zoloft) and citalopram (marketed as Celexa) seemed to increase the risk more than others, as did using more than one antidepressant at a time, according to the report in the September 25th Online First issue of BMJ.”

Paragraph six reads: “Sertraline [Zoloft] more than tripled the risk, while citalopram [Celexa] more than doubled it. Using more than one SSRI nearly quintupled the risk of the heart defect.”

http://www.reuters.com/article/healthNews/idUSTRE58O39F20090925

Antidepressants in pregnancy up heart defect risk
Fri Sep 25, 2009 9:58am EDT Email | Print | Share| Reprints | Single Page[-] Text [+]

By Anthony J. Brown, MD

NEW YORK (Reuters Health) – If you take antidepressants such as fluoxetine (marketed as Prozac) early in your pregnancy, you may be doubling the risk that your newborn will be born with a heart defect, according to a new study.

However, the vast majority of children born to women who take such antidepressants – known as selective serotonin reuptake inhibitors (SSRIs) – do not have such defects, the researchers are quick to note.

Earlier studies have tied SSRIs during pregnancy to heart defects, but also to even more serious birth defects. According to the new study of nearly half a million children born in Denmark between 1996 and 2003, however, only heart defects are likely to be associated with the antidepressants, note co-author Dr. Lars Henning Pedersen, from Aarhus University, Denmark, and colleagues.

Along with fluoxetine, sertraline (marketed as Zoloft) and citalopram (marketed as Celexa) seemed to increase the risk more than others, as did using more than one antidepressant at a time, according to the report in the September 25th Online First issue of BMJ.

Overall, SSRI use in early pregnancy, defined as 28 days before to 112 days after conception, doubled the risk of a particular kind of heart defect involving a piece of tissue that separates parts of the heart.

Sertraline more than tripled the risk, while citalopram more than doubled it. Using more than one SSRI nearly quintupled the risk of the heart defect.

However, the number of children born with such defects was still quite small: For about every 250 pregnant women who did not take SSRIs, one infant was born with the defect, while about two were born with the defect for every 250 women who took one SSRI, and four for every 200 mothers who took more than one.

Pedersen told Reuters Health that the results surprised the team.

Still, in an accompanying editorial, Dr. Christina Chambers, from the University of California, San Diego, comments that doctors and patients “need to balance the small risks associated with SSRIs against those associated with undertreatment or no treatment.”

SOURCE: BMJ, online September 25, 2009.

1,239 total views, 3 views today

ZOLOFT: Bizzare Suicide: New York

First two paragraphs read: “Toxicology results on Chris Corna released this week do not change the Westchester medical examiner’s conclusion that the popular Colorado restaurateur’s death was a suicide, but police are not closing their investigation.”

“The car Chris Corna of Steamboat Springs was driving very early May 18 crashed into a bridge abutment after he slit his throat, the medical examiner said. A bloodied kitchen knife was found in the car. Either trauma was enough to kill him, Medical Examiner Millard Hyland said at that time.”

Paragraph four reads: “Hyland said today that toxicology tests found appropriate amounts of a medicine, a tranquilizer used to treat anxiety, were in Corna’s system. The tranquilizer, sertraline, he said, is used in Zoloft.”

http://lohud.com/article/20090807/NEWS02/908070399/-1/SPORTS

Suicide ruling remains in Colo. restaurateur’s Port Chester death after toxicology results

By Leslie Korngold • lkorngol@lohud.com • August 7, 2009

Text Size: Normal | Large | Larger

PORT CHESTER – Toxicology results on Chris Corna released this week do not change the Westchester medical examiner’s conclusion that the popular Colorado restaurateur’s death was a suicide, but police are not closing their investigation.

The car Chris Corna of Steamboat Springs was driving very early May 18 crashed into a bridge abutment after he slit his throat, the medical examiner said. A bloodied kitchen knife was found in the car. Either trauma was enough to kill him, Medical Examiner Millard Hyland said at that time.

The initial finding of suicide elicited numerous e-mails and calls to The Journal News and Port Chester police from family and friends of the Steamboat Springs businessman saying it was not possible. He was on the East Coast having just proposed to a Greenwich woman and was doing well financially.

Hyland said today that toxicology tests found appropriate amounts of a medicine, a tranquilizer used to treat anxiety, were in Corna’s system. The tranquilizer, sertraline, he said, is used in Zoloft.

The “quantities are not over the top for someone taking it regularly,” the medical examiner said.

Hyland did not know if Corna was on the medication regularly. But even if it had been administered just this one time, it was still not enough to kill Corna and “it would be very difficult to attribute suicidal tendencies to the drug,” Hyland said.

There was no alcohol in Corna’s system, and the only other chemical present was a byproduct of the breakdown of sertraline, Hyland explained.

Port Chester police have been investigating the curious accident and wanted to see the toxicology report. Today, police said they were continuing their investigation into the circumstances of the death but would not elaborate

312 total views, no views today

Suspicious Suicide of Sister 1981 – NOW Solved 2009 – IMIPRAMINE. GENERIC FOR TOFRANIL

This is Lisa’s story of the sudden and tragic death of her sister Lori in 1981. Lori was 25 years old and Lisa was 13.  It took almost 3 decades for Lisa to find out the truth about her sister’s death. Here is Lisa’s story:

.

My sister Lori Died Suddenly on Sept. 22, 1981. She was 25 years old. I always knew my Sister’s sudden death was suspicious. I had searched for years for the answers to why, which included contacting the police department, and going over the report many times! Someone had to do this to her, she would not have killed herself! This I knew for sure! I would sit in my driveway where she lost her life, and look at my house many times over, and say how did you sit here, looking at our families home with your daughter, niece, sisters, and parents sleeping inside, how how could you have done this to us, and yourself?!

.
Nothing made sense then, and for the decades that followed. However, now almost three decades later “2009″ the truth has finally surfaced. I now have the answer I have searched for my entire life since that tragic morning I found her in her 1977 Buick with our father’s handgun in her lap. I promised her that morning I would not give up until I found the “truth” about what really happened to her. My sister loved life, and her family, and knew we loved her! She would not have taken her own life. So why did she?
.
Summary of Lori’s Story:
.
My sister moved home, and filed for divorce in 1980. I am her younger sister Lisa, and we spent most of this time together when she moved back home. I was going into the 8th grade that year. I was so happy that she was moving in with us, and that I would have time to spend with her. We were very close, very similar. Lori was a strong, smart woman, and she was determined to make it on her own! She worked for the county that we lived in, and was very well liked at her job. She also made enough money where she would be able to live. People that she worked with were shocked like everyone else was to hear about her sudden, so out of character death.
.
At the time she lived with us she was doing fine, going to work everyday, and taking one day at a time to rebuild her life. Throughout her divorce it was stressful, just as much as expected in any divorce situation. It is a life change. Suddenly the last month to weeks of her life I noticed that she had changed. I listened, and I watched her suddenly turn into someone I did not know. I could not figure it out? Why was she acting like this? Saying these things to me? Finding it funny to scare me? Lori suddenly started to talk about death, and dying! In which she would include me in her plans/ideas on how I/We could end her life!
.
Some examples are as follows:
.
1. Lori would loop a belt around her neck, and ask me to pull it as hard as I could until she stopped breathing!
.
2. Lori would ask me to come in the middle of the night, and put a pillow over her face to suffocate her in her sleep!
.
3. Lori would lay still in her bed, and when she heard me coming down the hallway she would lay still, and pretend to be dead. When I shook her to wake her up she would not move. She stayed so still until she couldn’t anymore, and started to laugh out loud hysterically at me, and then would say to me “I’m just joking Lisa, I just wanted to see what it would feel like to really be dead, and what you would do if I really was?! Then she would go on to say to me, “you don’t have to worry I wouldn’t really do anything, I’m too chicken!”
.
4. Lori suddenly changed by saying things to me like “HE” is in your room, closet and going to get you! Will you sleep with me in my room on the floor next to me? She also would say things that did not make sense like.. see this pin this will pop your face, see this curling iron, this will burn your face! It Never made sense the things she started to say..that was not her!
.
5. Lori suddenly at times would go from laughing, and joking about something into anger, (suddenly she pushed me into a file cabinet, it, and myself fell on the ground) Lori never would hurt anyone, especially me;  agitated, and confused mood. (suddenly she would look at me with sadness in her eyes, and say to me I don’t know why I am saying or doing these things.. I must be going crazy.
Lisa-Lori-ssri-suicide.jpg

Lisa & Lori

6. Something else happened shortly before her life ended in such a tragic horrific way. Lori suddenly became very sick she came down with the flu. She lost weight, she could not eat, drink, or get up out of bed she was very pale, and weak, frail looking. I felt so bad I could not help her feel better. I had never seen her so sick before. She could not hold food down and was growing weaker by the day.

7. Lori also suddenly started to fall asleep with her bible on her face. As if she were reading. praying for help to feel better. I had to take the bible of her face a few times when she finally was able to sit still, and take a short nap.
8. Lori’s sleeping patterns suddenly changed as well.
.
9. The night before she died, I remember it so clear. Lori kept rocking in our rocking chair that we had in our living room. She would not stop! She also was talking much faster than usual, and walking much faster as well. When I finally asked her to stop rocking so fast she just looked at me like she couldn’t stop, or didn’t want to. It was like someone was pushing her to rock. I thought it very odd at the time but soon overlooked it because of all her sudden behaviors had been so altered lately that I almost was getting use to the changes.
.
10. That night my sister’s were staying up to watch the Deer Hunter a movie that came out in the 80′s I believe. They wanted me to stay up also to watch it with them but I was tired, and only made through some of it. The Russian Roulette camp scene came up. Where each of the prisoners were made to put a loaded handgun to their heads, some chambers were full, some were not. Each prisoner was made to take a chance when it was their turn. If it was empty they lived. If it was not they died. Lori made the comment/question: Do you think if I did that it would work the first time? Then she laughed it off. Then she started talking about our German Shepherd Dog who was aging. Lori said what are we going to do with Champ when he dies? Then she said well it doesn’t matter, if we bury him the worms will eat him anyway! Again she laughed.

I went to bed soon after that part of the movie, I was very tired. Lori came into my bedroom late that night, and stood in my doorway. She was talking to me, and asked are you awake? I remember mumbling back to her yes, but was half asleep still. She looked at the last supper picture I had on the wall, and asked me who was so and so? I don’t remember the name she said. Then she went on to look at her daughters picture on my wall, and said aww, isn’t she so cute! Then the last thing she said to me was “Well I’ll see you in the morning ok?!” and off she went down the hallway, I heard the front door slam as it usually did behind her around that time of night. That night Lori was not sad, depressed, crying, or irritable, just sounded so full of life! Energized.

.
I did not know it then, but that was the last time I would hear her voice. That early morning of September 22, 1981 I was getting ready for school. I went into her bedroom to borrow a shirt of hers, and I quietly asked her if I could borrow it? Lori did not answer, so I took it, and got ready to catch the bus. As I walked out the front door down our driveway I had to pass her car, from a far distance all I could see was the color RED. My first thought was “here she goes again, She is trying to fool me again, and this time it looks like she used Ketchup!
.
Well as I got closer, I saw my sister through the car window, she was on her side with her head on the armrest of the passenger side door. I could see her face clearly, Her eyes were closed, and there was blood dripping from her mouth, and bottom lip onto the seat. Still I was in total disbelief. Our other sister ran back into the house right away, and was calling me to come with her. I stayed by the car window, pounding on the glass waiting for her move, or waiting for her to laugh because she fooled me again! She did not move, or laugh.
.
Our father came out of the house, and broke the driver side window, unlocked the door and got inside the car, reached across Lori’s body to unlock the passenger side door, ran around the car as fast as he could, got in and picked her up to hold her. Lori’s body lay across my fathers lap, and he just kept repeating WHY?

Our father came up to the house finally, hands and clothing full of blood, and said to me, your sister is gone. She had a open casket, I was not going to attend until a friend told me I should go say goodbye or I would regret it later. So I went. I finally went up to the casket where her body lay. All I could remember was the things she had said to me, and done those last weeks of her life. I was afraid, and confused to what had happened to her. It just never made sense! As I sat and looked across the room at her in the casket all I could think of was that this was not real. She was not Dead. She is pretending, etc. Even though In reality I did know she was gone. Just didn’t know why?!

*Lori did not drink,smoke, or do drugs- We had no answers. No clues so we thought. So for decades her sudden change, which followed to her sudden death remained “suspicious!”
.
THE NOTE SHE LEFT BEHIND SAID:
“IT’S NOBODY’S FAULT, I JUST FLIPPED!”
:)
(WITH A SMILEY FACE AT THE BOTTOM.)
.
Decades later the truth surfaced! Finally I was able to put it all together. In 2009 I was going through my sister’s box of things that I had packed away almost 28 years ago, off the top of her dresser. I came across many things I remembered from the time… one which included a medicine bottle. We knew Lori was put on a medicine to help her with the stress of her divorce, so it was not a surprise to me that I packed the bottle. Like I said we all knew she was taking something for anxiety. Back then it was similar to taking an advil. No big deal. As long as a doctor gave you something, it was ok to take. Safe.
.
However..the shock came to me when I typed the name of the drug into the computer just months ago. Slowly it all started to come together, and I mean all of it! As I read the side effects of the medication she was on, it all suddenly linked! Including the things she said, the things she did, the rocking in the chair, the things she was seeing that were not there, and finally to the flu like symptoms that she was displaying shortly before she ended her life at the young age of 25.

-NOW..EVEN THE NOTE SHE LEFT BEHIND MAKES SENSE!….SHE DID FLIP, LOST HER MIND, HOWEVER, SHE DID NOT KNOW IT WAS DUE TO THE CONCEALED SIDE EFFECTS OF A PRESCRIPTION DRUG SHE TOOK FOR JUST A FEW SHORT WEEKS!!

.
HERE IS THE WARNING ON THIS SAME DRUG TODAY (2013):
Imipramine and Suicides:
.
Your healthcare provider should monitor you (or your child) carefully when you are first starting an antidepressant. You should also be watchful for any signs of suicidal behavior. Contact your healthcare provider right away if you (or your child) have any of the following:
*Thoughts about death or *committing suicide, Suicide attempts, *Depression or anxiety that is new or worse, *Agitation, restlessness, or panic attacks
*Trouble sleeping (insomnia), *Irritability that is new or worse, *Aggressive, angry, or violent behavior, *Acting on dangerous impulses, *Unusually increased talking or activity*Akathisia
An analysis of a large clinical trial published in the British Journal of Psychiatry in 2008 estimated that up to 35 percent of people taking antipsychotic drugs experience akathisia.
.
Symptoms include: Fidgety movements*, Leg swinging while sitting*, Rocking from foot to foot or pacing*, Motor restlessness; inability to sit still*, Feelings of anxiety*, Insomnia*. The combination of these symptoms and depression and impulsiveness may also contribute to aggression and suicide in some patients. Other strange changes in mood or behavior. (* I put a star next to every side effect she had!)
.
BLACK BOX WARNING (2004)
http://www.accessdata.fda.gov/psn/transcript.cfm?show=34 Today we have commercials warning of these dangers. We also have computers where we can do our own research. Back then, we had nothing! Some say maybe no-one knew back then… Not true! Facts below:
.
Pharmacosis:
* The first descriptions of a drug causing suicide came in 1955. A few years later in 1958 and again in 1959 the problem was described with imipramine.* Treatment induced suicide became a prominent media issue in 1990 with a paper by Teicher and Cole. (MY SISTER DID NOT HAVE TO DIE!) *It was not until 2004 that regulators and companies conceded that these drugs can cause a problem.
.
Closure.
.
In 2009 I was able to give our parents some kind of closure to Lori’s death, however, this in no way made up for the three plus decades of pain and suffering they as parents had to endure. Our Mother said: You mean she died because people had to be greedy, and make money? Our Father said: It don’t matter now, because she is gone, and nobody will care! HAD WE KNOWN THE CONCEALED SIDE EFFECTS OF IMIPRAMINE, MY SISTER WOULD BE ALIVE TODAY!
.
WELL MY STORY IS NOW ONLINE, AND PEOPLE DO CARE, AND HOPEFULLY LIVES CAN BE SAVED BY READING HER STORY! IN LOVING MEMORY OF MY SISTER… SHE MAY NOW, AFTER ALMOST THREE DECADES, REST IN PEACE.
I LOVE YOU.
.
.

2,552 total views, 10 views today

Zoloft SSRI Antidepressant Destroyed my Life

It’s now August of 2009, just past a year after being discharged from the psychiatric hospital.  I’ve been off Zoloft since March 2009 and am finally feeling like a human being again.  Fortunately, I don’t seem to have any neurological damage, memory impairment, concentration troubles or other lasting symptoms.

I’m 48 years old and my introduction to Zoloft began when I was 34. I’ve since learned that the symptoms of fatigue and difficulty sleeping and concentrating that I was having at that time were due to over-work and adrenal exhaustion. That doctor had me fill out a questionnaire and then spent maybe 10 minutes with me before giving me free samples of Zoloft.   Had I known then, what I know now?… And I must forgive the past and not dwell on it in order to heal.

In June of 2008, my nutritionist who was treating me with amino acid therapy took me off Zoloft abruptly.  This caused me to go into a manic state, which I had never experienced before.  It also brought up a lot of anger.  After about a ten days, my wife and I figured out it was the discontinuation of Zoloft that was causing all these problems, so I went back on it.

Because of all my weird behavior, I had left the house and was staying at a hotel.  My wife got my sister involved and she stayed with me for a couple of days but didn’t bring along her bi-polar medications.  I remember distinctly the night of July 13th:  I slept from about 9pm to 5am, went for a work out and did my meditation.  I was definitely stabilizing.

Then my sister took me into town, my wife and I had another fight and, in my anger and frustration, I broke the rear view mirror off my sister’s car.  This caused her to freak out.  We had picked up her meds and agreed to go back to the hotel and take a nap.  I later learned that she had already called the police.

When we arrived at the hotel, the cops came to my door (hands on their holstered guns) and ordered me out of the car.  They hand cuffed me, searched me and put me in the squad car.  Then, as I later learned, my sister and wife had a discussion about “wether or not to tell the police that I had threatened her.”  My sister told the police a lie, that I had threatened her with a gun and I was hauled off to the ER where I was doped up with an injection.

Later I was taken to the psychiatric hospital where I was asked to sign a bunch of forms and “releases.”  How absurd!  I was only semi-consicouss at the time.

At the hospital I was taken off the Zoloft and diagnosed as bi-polar.  Of course, this through me into another withdrawal episode and made me manic and aggressive again.

I want to point out that I have no history of violence, have never been in any sort of brawl, have never been arrested, have never before been put in handcuffs, no DUI tickets and even a clean driving record.

The hospital changed my drugs every few days.  Zyprexa, Lithium, Depakote, Abilify, etc.  After 20 days, I was discharged. The insurance and family money was expended, so I was well, right?

Far from it:  My wife filed for divorce.  I lost access to my home, which was also my office.  She cleaned out the company bank account, etc.

Eventually, I lost pretty much everything and got saddled with all our debt and received none of the assets due to a waiver of “appearance” I signed 3 days out of the hospital.  We had agreed on a negotiated, one lawyer divorce, but I ended up getting totally screwed.

Over the past 12 months, I’ve lived in 5 states.  I’ve had a couple of “room and board” jobs and stayed with friends.  Fortunately, my mother has been able to give me some financial support, so I haven’t been without the basic necessities of life.  Through a friend, I found Ann Blake-Tracy and she helped me understand what happened to me and gave me phone support while I finished the detox from the Zoloft these past few months.

Now, I’m well enough that I’m looking for  a job again so I can restart my life.

I’m certainly not bipolar.  What a bunch of total bullshit.  All I’m taking right now is 0.5 mg of Klonopin (Clonazepam) twice a day to help with anxiety and sleep.

I used to have a pretty normal life.  I made a six figure income.  My wife (18 years of marriage) didn’t have to work. We had a nice house and the swimming pool I had wanted since I was a child.  Now, all that’s gone.  All because of a stupid little pill and all the people that don’t know what the hell their doing with all these powerful drugs.

During the 13 years I was on SSRI Antidepressants, I saw several different psychiatrists and doctors.  They experimented on me with many different drugs: Effexor, Celexa, Abilify, Alprazolam, Clonazepam (Klonopin), Depakote, Lunesta, Trazodone, Xanax, Zyprexa and of course Zoloft (Sertraline).

Of all the drugs, Lamictal was the worst.  Once the doctor increased the dose from 50 mg a day to 200 mg a day (I’ve since found out that is NOT an increase in accordance with the manufacturers instructions) I had horrible, disgusting nightmares every single night and became highly suicidal.  This happened in October of 2008, and freaked me out so much that I went back on Zoloft and some other drugs so that I could get my sleep.

During all these crazy times, I have survived because of my spiritual faith, the generosity of my mother and some good friends and Divine Grace.  Also, because of the various nutritionists I’ve had over the years, I’ve learned how to eat well and take the right supplements.  Cenitol by metagenics is magnesium supplement that has been especially helpful with relaxing me and helping me sleep.  I order that online at:  http://www.janethumphrey.meta-ehealth.com.

Lastly, I would like to mention that none of these doctors I saw gave me any sort of what I would call informed consent.  I was never informed about all the adverse reactions and side-effects that I’ve now learned were well known back then.  None of the doctors explained that, according to their view of brain chemical imbalance, I would need to stay on these SSRI Antidepressants for the rest of my life.  None of the doctors EVER explained discontinuation syndrome etc, etc, etc.

These drugs manufactures and the doctors that push these drugs are all involved in a horrible scam, the tragic consequences of which yet to become fully manifest.

My intense gratitude to Ann Blake-Tracy and the good work she is doing!

888 total views, 2 views today

List of SSRI Antidepressants and Common Psychiatric Drugs

A
Abilify, Adapin, Adderall, Alepam, Alertec, Aloperidin, Alplax, Alprax, Alprazolam, Alviz, Alzolam, Amantadine, Ambien, Amisulpride, Amitriptyline, Amoxapine, Anafranil, Anatensol, Ansial, Ansiced, Antabus, Antabuse, Antideprin, Anxiron, Apo-Alpraz, Apo-Primidone, Apo-Sertral, Aponal, Apozepam, Aripiprazole, Aropax, Artane, Asendin, Asendis, Asentra, Ativan, Atomoxetine, Aurorix, Aventyl, Axoren

B
Beneficat, Bimaran, Bioperidolo, Biston, Brotopon, Bespar, Bupropion, Buspar, Buspimen, Buspinol, Buspirone, Buspisal

C
Calepsin, Calcium carbonate, Calcium carbimide, Calmax, Carbamazepine, Carbatrol, Carbolith, Celexa, Chlordiazepoxide, Chlorpromazine, Cibalith-S, Cipralex, Citalopram, Clomipramine, Clonazepam, Clozapine, Clozaril, Concerta, Constan, Convulex, Cylert

D
Dalmane, Dapotum, Defanyl, Demolox, Depakene, Depakote, Deprax, Deprilept, Deroxat, Desipramine, Desirel, Desoxyn, Desyrel, Dexedrine, Dextroamphetamine, Dextrostat, Diapam, Diazepam, Dilantin, Disulfiram, Divalproex, Dogmatil, Doxepin, Dozic, Duralith

E
Edronax, Efectin, Effexor (Efexor), Eglonyl, Einalon S, Elavil, Endep, Epanutin, Epitol, Equetro, Escitalopram, Eskalith, Eskazinyl, Eskazine, Etrafon, Eukystol

F
Faverin, Fazaclo, Fevarin, Finlepsin, Fludecate, Flunanthate, Fluoxetine, Fluphenazine, Flurazepam, Fluvoxamine, Focalin

G
Geodon, Gladem

H
Halcion, Halomonth, Haldol, Haloperidol, Halosten

I
Imipramine, Imovane

J
Janimine, Jatroneural

K
Kalma, Keselan, Klonopin

L
Lamotrigine, Largactil, Levomepromazine, Levoprome, Leponex, Lexapro, Libritabs, Librium, Linton, Liskantin, Lithane, Lithium, Lithizine, Lithobid, Lithonate, Lithotabs, Lorazepam, Loxapac, Loxapine, Loxitane, Ludiomil, Lunesta, Lustral, Luvox, Lyogen, Lecital

M
Manegan, Manerix, Maprotiline, Mellaril, Melleretten, Melleril, Meresa, Mesoridazine, Metadate, Methamphetamine, Methotrimeprazine, Methylin, Methylphenidate, Minitran, Moclobemide, Modafinil, Modalina, Modecate, Moditen, Molipaxin, Moxadil, Murelax, Myidone, Mylepsinum, Mysoline

N
Nardil, Narol, Navane, Nefazodone, Neoperidol, Norebox, Normison, Norpramine, Nortriptyline, Novodorm

O
Olanzapine, Omca, Orap, Oxazepam

P
Pamelor, Parnate, Paroxetine, Paxil, Peluces, Pemoline, Permitil, Perphenazine, Pertofrane, Phenelzine, Phenytoin, Pimozide, Piportil, Pipotiazine, Pragmarel, Primidone, Prolift, Prolixin, Protriptyline, Provigil, Prozac, Prysoline, Psymion

Q
Quetiapine

R
Ralozam, Reboxetine, Resimatil, Restoril, Restyl, Rhotrimine, Risperdal, Risperidone, Rispolept, Ritalin, Rivotril, Rubifen, Rozerem

S
Sediten, Seduxen, Selecten, Serax, Serenace, Serepax, Serenase, Serentil, Seresta, Serlain, Serlift, Seroquel, Seroxat, Sertan, Sertraline, Serzone, Sevinol, Sideril, Sigaperidol, Sinequan, Sinqualone, Sinquan, Sirtal, Solanax, Solian, Solvex, Songar, Stazepin, Stelazine, Stilnox, Stimuloton, Strattera, Sulpiride, Sulpiride Ratiopharm, Sulpiride Neurazpharm, Surmontil, Symbyax, Symmetrel

T
Tafil, Tavor, Taxagon, Tegretol, Telesmin, Temazepam, Temesta, Temposil, Terfluzine, Thioridazine, Thiothixene, Thombran, Thorazine, Timonil, Tofranil, Trancin, Tranax, Trankimazin, Tranquinal, Tranylcypromine, Trazalon, Trazodone, Trazonil, Trialodine, Triazolam, Trifluoperazine, Trihexane, Trihexyphenidyl, Trilafon, Trimipramine, Triptil, Trittico, Tryptanol

U
V
Valium, Valproate, Valproic acid, Valrelease, Venlafaxine, Vestra, Vigicer, Vivactil

W
Wellbutrin

X
Xanax, Xanor, Xydep

Z
Zamhexal, Zeldox, Zimovane, Zispin, Ziprasidone, Zolarem, Zoldac, Zoloft, Zolpidem, Zonalon, Zopiclone, Zydis, Zyprexa

442 total views, 1 views today

Experts: Women are drinking more, DUIs are up 28.8% from 1998-2007

Note from Ann Blake-Tracy: After researching and warning for two decades that this crisis with alcohol consumption would come, I can tell you the reason so many women are now drinking is because they are the main ones taking antidepressants which in turn cause overwhelming cravings for alcohol. And it has long been known that women suffer more adverse reactions to antidepressants than men do.

But why cravings for alcohol? These drugs drop the blood sugar causing cravings for sugar and/or alcohol and NutraSweet. Sugar and alcohol initially bring the blood sugar up quickly causing one to instinctively reach for them in a “self medicating” way because they quickly address the low blood sugar level. The problem with doing this is that both substances then drop the sugar levels even lower than before thus producing a vicious cycle of craving more and more sugar and/or alcohol. (To read the science behind this go to www.drugawareness.org)
Another aspect to this increased use in alcohol being tied to antidepressant use is the fact that antidepressants produce mania or Bipolar Disorder so frequently. (See the research article we posted earlier this week showing that 81% of those diagnosed with Bipolar Disorder have been found to have previously taken antidepressants or Ritalin.)
Initially doctors refused to prescribe the first SSRI, Prozac, because of its strong potential to chemically induce mania. There are several types of mania that are recognized. Many have never even heard of these types of mania. And most do not think of these various types of mania when they hear the term Bipolar. Let’s list just a few to shed some additional light on this drinking problem women, who have always taken more antidepressants than men, have developed since these drugs have become so widespread in use.

Pyromania: A compulsion to start fires
Kleptomania: A compulsion to embezzle, shoplift, commit robberies
Dipsomania: An uncontrollable urge to drink alcohol
Nymphomania and erotomania: Sexual compulsions – a pathologic preoccupation with sexual fantasies or activities

So there it is in black and white plain as day – one of the forms of mania, dipsomania, is described as an “uncontrollable urge to drink alcohol.” Could it be any clearer?

Learn More

http://www.drugawareness.org/wp-content/uploads/wpsc/product_images/thumbnails/helpicant.jpg
Order Today

And look at one of the comments from the article below:
“Younger women feel more empowered, more equal to men, and have been beginning to exhibit the same uninhibited behaviors as men,” said Chris Cochran of the California Office of Traffic Safety.
Does that not describe manic behavior – “empowered” or all powerful with grandiose thoughts of one’s self and “uninhibited”? Those have always been earmarks warning of mania.
Hopefully this news about women and drinking will FINALLY wake America up to what first caught my attention with the use of antidepressants – the OVERWHELMING out-of-character cravings for alcohol that is produced by these drugs. (Find much more additional information on this subject at www.drugawareness.org)
Ann Blake Tracy, Ph.D., Executive Director,
International Coalition For Drug Awareness
Website:
www.drugawareness.org & www.ssristories.drugawareness.org
Author: Prozac: Panacea or Pandora? – Our Serotonin Nightmare
& CD or audio tape on safe withdrawal: “Help! I Can’t Get
Off My Antidepressant!”
Order Number:

Experts: Women are drinking more, DUIs are up

http://us.rd.yahoo.com/dailynews/ap/brand/SIG=br2v03/*http://www.ap.org

AP – Graphic shows driving under the influence arrests for men and women for 1998 and 2007; includes alcohol-impaired …
By LISA A. FLAM, Associated Press Writer Lisa A. Flam, Associated Press Writer 10 mins ago

NEW YORK – It seemed too horrendous even to imagine. But the case of the mother who caused a deadly wrong-way crash while drunk and stoned is part of a disturbing trend: Women in the U.S. are drinking more, and drunken-driving arrests among women are rising rapidly while falling among men.

And some of those women, as in the New York case, are getting behind the wheel with kids in the back.

Men still drink more than women and are responsible for more drunken-driving cases. But the gap is narrowing, and among the reasons cited are that women are feeling greater pressures at work and home, they are driving more, and they are behaving more recklessly.

“Younger women feel more empowered, more equal to men, and have been beginning to exhibit the same uninhibited behaviors as men,” said Chris Cochran of the California Office of Traffic Safety.

Another possible reason cited for the rising arrests: Police are less likely to let women off the hook these days.

Nationwide, the number of women arrested for driving under the influence of alcohol or drugs was 28.8 percent higher in 2007 than it was in 1998, while the number of men arrested was 7.5 percent lower, according to FBI figures that cover about 56 percent of the country. (Despite the incomplete sample, Alfred Blumstein, a Carnegie Mellon University criminologist, said the trend probably holds true for the country as a whole.)

“Women are picking up some of the dangerously bad habits of men,” said Chuck Hurley, CEO of Mothers Against Drunk Driving.

In New York’s Westchester County, where Diane Schuler’s crash killed her and seven other people last month, the number of women arrested for drunken driving is up 2 percent this year, and officers said they are noticing more women with children in the back seat.

“We realized for the last two to three years, the pattern of more female drivers, particularly mothers with kids in their cars, getting arrested for drunk driving,” said Tom Meier, director of Drug Prevention and Stop DWI for the county.

In one case there, a woman out clubbing with her teenage daughter was sent to prison for causing a wrong-way crash that killed her daughter’s friend.

Another woman was charged with driving drunk after witnesses said she had been drinking all day before going to pick up her children at school. Authorities said the children were scared during the ride, and once they got home, they jumped out of the car, ran to a neighbor’s house and told an adult, who called police. The mother lay passed out in the car, and police said her blood alcohol level was 0.27 percent — more than three times the legal limit.

In California, based on the same FBI figures, women accounted for 18.8 percent of all DUI arrests in 2007, up from 13.5 percent in 1998, according to the California Office of Traffic Safety.

Nearly 250 youngsters were killed in alcohol-related crashes in the U.S. in 2007, and most of them were passengers in the car with the impaired driver, according to the National Highway Safety Administration.

“Drunk drivers often carry their kids with them,” said MADD’s Hurley. “It’s the ultimate form of child abuse.”

Arrests of drunken mothers with children in the car remain rare, but police officers can generally list a few.

In the Chicago suburb of Wheaton, Supreme Court Justice Antonin Scalia‘s daughter was stopped by police after she pulled away from a McDonald’s with three of her kids in the car. She pleaded guilty to drunken driving and was sentenced to 18 months of court supervision.

Sgt. Glen Williams of the Creve Coeur, Mo., police department recalls stopping a suspected drunken driver on her way to pick up two preschoolers.

Sometime later, “she told me it actually changed her life, getting arrested,” he said. “She was forced to get help and realized she’d had a problem.”

The increase in arrests comes as women are drinking excessively more than in the past.

One federal study found that the number of women who reported abusing alcohol (having at least four drinks in a day) rose from 1.5 percent to 2.6 percent over the 10-year period that ended in 2002. For women ages 30 to 44, Schuler’s age group, the number more than doubled, from 1.5 percent to 3.3 percent.

The problem has caught the attention of the federal government. The Transportation Department’s annual crackdown on drunken driving, which begins later this month, will focus on women.

“There’s the impression out there that drunk driving is strictly a male issue, and it is certainly not the case,” said Rae Tyson, spokesman for the National Highway Traffic Safety Administration. “There are a number of parts of the country where, in fact, the majority of impaired drivers involved in fatal crashes are female.”

Schuler’s relatives have denied she was an alcoholic and said they were shocked to learn of her drug and alcohol use before the July 26 crash. The wreck, about 35 miles north of New York City, killed Schuler, her 2-year-old daughter, her three nieces and three men in an oncoming SUV she hit with her minivan. Schuler’s 5-year-old son survived his injuries.

Schuler, a cable company executive, could have had a drinking problem that her family didn’t know about, said Elaine Ducharme, a psychologist in Connecticut who has seen more excessive drinking, overeating, smoking and drug abuse during the recession.

Unlike men, women tend to drink at home and alone, which allows them to conceal a problem more easily.

Because of this, they seek treatment less often than men, and when they do, it is at a later stage, often when something catastrophic has already happened, said Dr. Petros Levounis, director of the Addiction Institute of New York at St. Luke’s-Roosevelt Hospital Center.

“Our society has taught us that women have an extra burden to be the perfect mothers and perfect wives and perfect daughters and perfect everything,” Levounis said. “They tend to go to great lengths to keep everything intact from an external viewpoint while internally, they are in ruins.”

In the current recession, women’s incomes have become more important because so many men have lost their jobs, experts say. Men are helping out more at home, but working mothers still have the bulk of the child rearing responsibilities.

“Because of that, they have a bigger burden then most men do,” said clinical psychologist Carol Goldman. “We have to look at the pressures on women these days. They have to be the supermom.”

And just becoming a parent doesn’t mean people will stop using drugs or alcohol, Ducharme said: “If you have a real addictive personality, just having a child isn’t going to make the difference.”

___

Associated Press writers Solvej Schou in Los Angeles, Mark Tarm in Chicago and Betsy Taylor in St. Louis contributed to this report.


368 total views, no views today

Kauffman Study – (SSRI) Drugs: More Risks Than Benefits?

Journal of American Physicians and Surgeons Volume 14 Number 1 Spring 2009

SSRI Bombshell by Joel M. Kauffman, Ph.D. Tuesday, March 31st, 2009

Selective Serotonin Reuptake Inhibitor (SSRI) Drugs: More Risks Than Benefits?

Joel M. Kauffman, Ph.D.

ABSTRACT

Anecdotal reports have suggested that selective serotonin reuptake inhibitors (SSRIs) may cause suicidal or violent behavior in some patients. Because of the publicity surrounding certain events, and the numerous lawsuits that have been filed, a review of benefits and risks is needed.

At most 30% of patients receive a benefit from SSRIs beyond the large placebo effect in certain mental conditions, especially depression, according to a recent meta-analysis of published trials. An equally recent meta-analysis of all SSRI trials submitted to the FDA showed a small benefit for the severely depressed patients only. Many early unpublished trials did not show any benefit. Adverse effects are common, occurring in up to 75% of subjects.

Severe adverse effects may be underreported.

Meta- analyses of controlled trials did not include any actual suicides or murders, but only suicidality, some finding, in 1991 and 2007, no evidence even of suicidality.

Other meta-analyses using many of the same trials found that suicidality doubled to 1 in 500 on SSRIs compared with placebo or non-SSRI antidepressants, but did not include any actual suicides or murders. The trial designs were devised by SSRI makers to prevent reports of suicides, by eliminating subjects with the slightest trace of suicidal tendencies. Retrospective studies by others showed actual suicides on SSRIs with a relative risk (RR) of 2–3 compared with non-SSRI antidepressants, with an increased incidence of 123/100,000. Lower doses than the smallest available ones were found to maintain benefits in a majority of patients while reducing risks.

table_03_zoloftbusted1

[PLEASE NOTE THAT THE SSRISTORIES DATABASE REFERRED TO BY DR. KAUFFMAN IN THIS STUDY IS NO LONGER POSTED AT THE URL LISTED ABOVE BUT HAS BEEN MOVED TO THE URL www.ssristories.NET ]

No causal connection between SSRIs and suicide and/or violence has been proved; neither has it been ruled out. Physicians need to be vigilant, and aware of legal precedents that may subject them to enhanced liability when prescribing these drugs. The Genesis of SSRIs Fluoxetine (Prozac in the U.S., see Table 1), introduced in 1988 to combat depression, was the fourth selective serotonin reuptake inhibitor (SSRI) on the U.S. market, after being seriously considered by Eli Lilly as an antihypertensive drug. Unlike the earlier “tricyclics” (amitripyline, clomipramine, dothiepin, imipramine, etc.) and other drug classes, SSRIs acted on the brain to raise levels of the neurotransmitter serotonin without raising the levels of norepinephrine. This was thought to be a benefit in treatment of depression, and later anxiety, panic, social phobia, obsessive- compulsive disorder (OCD) , and many other conditions. The SSRIs listed in Table 1 are among the most frequently prescribed in the U.S., and compete with the five non- SSRIs shown, and others.

ssri-drug-table1

Benefits of SSRIs

A prominent recent meta-analysis of Bridge et al. included 27 trials of SSRIs for three defined mental conditions: major depressive disorder (MDD), OCD, and non-OCD anxiety disorders. Benefits, compared with placebo, were found to be highly statistically significant. For MDD, data from 13 trials showed benefit in 61% vs. 50% on placebo, a gain of 11% absolute (NNT=10), <0.001 for all ages of participants. For OCD, data from six trials showed benefit in 52% vs. 32% on placebo, a gain of 20% absolute (NNT=5), <0.001 for all ages. For non-OCD anxiety, data from 6 trials showed benefit in 69% vs. 39% on placebo, a gain of 30% absolute (NNT=3), <0.001 for all ages. These results represent the maximum expectation of benefit from SSRIs since 22 of the 27 trials were financially supported by SSRI makers, and thus subject to the routinely positive bias of industry-sponsored clinical trials. Jay S. Cohen, M.D., author of the 2001 book , wrote that half his patients did well on fluoxetine, but he noted a high incidence (50%) with side-effects. Cohen also cited a pre-approval study showing that the standard 20 mg per day starting dose helped 65% of patients, while 5 mg helped 54%, so Cohen became one of the pioneers in using lower doses before Lilly made them available. The 1996 entry for paroxetine, at least, confirmed that the 17 most common side-effects were dose-dependent.

In four observational cohort studies of four common SSRIs reported by physicians as part of the prescription-event monitoring program in the UK, with more than 10,000 patients in each drug group, only 36% of the physicians reported fluvoxamine as effective, compared with 60% for fluoxetine, sertraline, and paroxetine. These possible benefit rates, which include the placebo effect, parallel the percentage of patients remaining on the drug for 2 months.

See: Over Dose: the Case Against the Drug Companies

An old trial of placebo for anxious and depressed subjects reduced distress in 43%. Three meta-analyses of the antidepressant literature that appeared in the 1990s independently concluded that two-thirds of the effectiveness attributed to SSRIs is actually placebo effect. In a series of nine controlled studies on hospitalized patients with depression, 57% of those given placebo showed improvement in 2–6 weeks. A 1998 meta-analysis of 47 trials on antidepressant medication including SSRIs indicated that 75% of the response to them was duplicated by placebo. This meta-analysis was criticized on several grounds. Therefore, Irving Kirsch, Ph.D., of the University of Connecticut, with other authors, obtained data submitted to the FDA on every placebo-controlled clinical trial on the six most widely used SSRIs, and published a meta-analysis on 47 trials, finding a small, clinically insignificant effect.

This work was updated in 2008:

Analyses of datasets including unpublished as well as published clinical trials reveal smaller effects that fall well below recommended criteria for clinical effectiveness. Specifically, a meta-analysis of clinical trial data submitted to the U.S. Food and Drug Administration (FDA) revealed a mean drug–placebo difference in improvement scores of 1.80 points on the Hamilton Rating Scale of Depression (HRSD), whereas the National Institute for Clinical Excellence (NICE) used a drug–placebo difference of three points as a criterion for clinical significance when establishing guidelines for the treatment of depression in the United Kingdom. Kirsch et al. concluded that the updated findings from 35 carefully vetted trials suggest that, compared with placebo, the four new- generation antidepressants ( fluoxetine, venlfaxine, nefazodone, and paroxetine) do not produce clinically significant improvements in depression in patients who initially have moderate or even severe depression.

They show statistically significant but clinically minor effects only in the most severely depressed patients. Moreover, the significance of the effect probably is based on a decreased responsiveness to placebo, rather than increased responsiveness to medication. Given these results, the researchers conclude that there is little reason to prescribe new- generation antidepressant medications to any but the most severely depressed patients unless alternative treatments have been ineffective. In addition, they write that the decreased placebo response in extremely depressed patients, combined with a response to antidepressants comparable to that of less severely depressed patients, is a potentially important insight that should be investigated further.

Even these unimpressive findings exaggerated the benefits of antidepressants. In three fluoxetine trials and in the three sertraline trials for which data were reported, the protocol allowed replacement of patients who, in the investigators’ judgment, were not improving after 2 weeks. The trials also included a 1–2 week washout period, during which patients were given a placebo prior to randomization. Those whose scores improved 20% or more were excluded from the study. In 25 trials, the use of other psychoactive medication was reported. In most trials, a chloral hydrate sedative was permitted in doses ranging from 500 mg to 2,000 mg per day. Other psychoactive medication was usually prohibited but still reported as having been taken in several trials.

Perhaps such considerations led David Healy, M.D., an SSRI expert, to his conclusion that “…these drugs do not convincingly work….” His evidence came from early unpublished clinical trials whose results were revealed to him at FDA hearings. For fluoxetine, Healy noted four trials with a positive result and four without. For sertraline, only one of five early studies showed benefit. Because of the huge placebo effect, 32–75%, most physicians unfamiliar with the studies revealing this effect are likely, in my opinion, to say that one-third to two-thirds of their patients are improved on SSRIs. This would also explain Dr. Jay S. Cohen’s findings on lower doses of fluoxetine.

SSRIs reportedly interact with 40 other drugs to cause “serotonin syndrome.”

This presents as twitching, tremors, rigidity, fever, confusion, or agitation. Serotonin/norepinephrine reuptake inhibitors (SNRIs) also may cause serotonin syndrome by interactions. Most tricyclic depressants do not have these interactions, with the exception of amitriptyline.

In a controlled trial of paroxetine vs. clomipramine sponsored by GlaxoSmithKline, 75% of the subjects had an adverse effect on paroxetine, 21% had a severe adverse effect, and 13% committed a suicidal act (1 in 8). The 1996 entry for paroxetine lists 17 side-effects with an incidence of ≥ 5% for approved doses.

They are: asthenia, sweating, constipation, decreased appetite, diarrhea (up to 15%), dry mouth (up to 21%), nausea (up to 36%), anxiety, dizziness, nervousness, paresthesia, somnolence (up to 22%), tremor (up to 15%), blurred vision, abnormal ejaculation, impotence, and other male genital disorders. Fully 31 additional side effects with an incidence at least 1% greater than placebo were listed, including uncontrollable yawning.

Murder, suicide, and suicidality were NOT [emphasis added] included.

Nor were they on comparable lists for fluvoxamine, or sertraline. For fluvoxamine, suicide were separately listed as “infrequent.”

For fluoxetine, suicidal ideation was listed as a voluntary report not proved to be drug related. For sertraline, suicidal ideation and attempt were listed separately as “infrequent.”

The entry for venlafaxine was: “…the possibility of a suicide attempt is inherent in depression.” Not found in the was weight gain, which Cohen lists as a serious side effect.

Typical dropout rates in recent trials are claimed to be 5% (see below), but these must be short trials, or trials with a run-in period. In a meta-analysis of 62 earlier trials with a total of 6,000 subjects, the mean total dropout rate and the proportion of dropouts due to side effects appear comparable to results in general practice: total dropout rates of between 30% and 70% have been reported by 6 weeks, of which some 30%–40% are attributed to side effects and the rest to failure of treatment. Early findings of severe adverse effects by SSRI makers came to light only after the class was established. Of 53 healthy volunteer studies on fluoxetine, the results of only 12 were openly reported.

From 35 healthy volunteer studies on paroxetine, pre-launch, the results of only 14 appeared. From 35 pre-launch healthy volunteer studies on sertraline, only seven appeared. Among the unpublished trials, there was one in which all volunteers dropped out because of agitation (akathisia). In published work on sertraline, data excluded material on behavioral toxicity, including at least one suicide of a Adverse Effects of healthy volunteer, and in a different trial, 2 of 20 volunteers became intensely suicidal. This last is consistent with the dropout rate of 5% for agitation alone in actual trials. It is also consistent with Lilly’s animal studies, in which previously friendly cats treated with fluoxetine started growling and hissing—an unheeded warning.

Just a year after fluoxetine was introduced, Bill Forsyth of Maui, Hawaii, had taken it for only 12 days when he committed one of the first murder/suicides attributed to any SSRI.

In the same year Joseph Wesbecker killed eight others and himself in a Louisville, Ky., printing plant where he worked, after 4 weeks on fluoxetine. Yet as early as 1986, clinical trials showed a rate of 12.5 suicides per 1,000 subjects on fluoxetine vs. 3.8 on older non-SSRIs vs. 2.5 on placebo! An internal 1985 Lilly document found even worse results and said that benefits were less than risks. Such documents were released into the public domain by Lilly as part of the settlement in the Wesbecker case. Fifteen more “anecdotes” of murder/suicide, three with sertraline, were listed by DeGrandpre.

Lilly’s denials of a link to murder/suicide on national television and elsewhere cited a sponsored meta-analysis in in 1991, which exonerated fluoxetine as a cause of suicidal acts or thoughts without even mentioning actual murder or suicide. This study included only 3,067 patients of the 26,000 in the clinical trials it utilized. None of the trials had a declared endpoint of suicidality.

Some of the trials had been rejected by the FDA. No mention was made that Lilly had had benzodiazepines co-prescribed to minimizethe agitation that had been recognized with fluoxetine alone. The 5% dropout rate for anxiety and agitation (akathisia) would have taken out the most likely candidates for suicide. Nevertheless, the 1991 study had its intended effect. For example, in 2006 a 900-page tome entitled , which was aimed at attorneys, cited this study, and failed lawsuits concerning SSRIs. The 2007 meta-analysis by Bridge et al. may be influenced by indirect conflicts of interest that are hard to prove based on the financial disclosures.

Their paper pooled excess risk above placebo for “suicidal ideation/suicide attempt” from 27 trials. The excess risk was said to be 0.7% and statistically significant across all indications, but significant within each indication. Of the 27 trials, only five were sponsored by the drug maker, and one of these, the 2004 Treatment for Adolescents with Depression (TADS) study of fluoxetine, had the highest rate of suicidality—7% above placebo. Most of the same trials were used in a meta-analysis by the FDA, which found a statistically significant excess risk of 2% (4% vs. 2% on placebo, 1 in 50 more). Bridge et al. used a random-effects calculation, while the FDA used a fixed-effects calculation.

In commenting on the negative findings, Bridge et al. write: “No study [in our meta-analysis] was designed to examine suicidal ideation/suicide attempt as a study outcome, and in fact most trials were conducted in patients who had been carefully screened to exclude youths at risk.” No actual murders or suicides associated with SSRI use were reported. Did the designs of the studies preclude detection or reporting?

The Bridge meta-analysis was not just a vindication of SSRIs, as communicated to the by Gilbert Ross, M.D., Medical Director of the American Council on Science & Health. Ross went further, commenting that the FDA “Black Box warning” (see below) was counterproductive because it was discouraging the use of antidepressants! Ross speculated that the lethal rampage of the Virginia Tech shooter might have resulted from premature cessation of medications.

SSRIs in general have long lifetimes in the body. Fluoxetine and its active metabolite in particular have a half-life of 16 days, according to the 1996 . In a reexamination of trials in which suicides or attempts during the inadequate washout period were not blamed on the drug, it was shown that the relative risk (RR) of suicidal acts ranged from 3 for sertraline to 10 for fluoxetine.

A concurrent meta-analysis of 24 trials by Kaizar et al. utilized Bayesian statistics, a valid choice, in my opinion, because data do not have to follow a Gaussian or normal curve to yield valid results, and this method can be used to revise probabilities to determine whether a specific effect was due to a specific cause. They found an association between SSRI use and suicidality with odds ratios of 2.3 (95% confidence interval [CI] 1.3-3.8), when the diagnosis was MDD, not OCD, anxiety, nor ADHD. Non-SSRI antidepressants were said to have no association with suicide. This supports the FDA’s findings and requirement, as of October, 2004, for a Black Box warning for all SSRIs, to monitor children and adolescents for suicidality. Kaizar et al. were concerned that there were no completed suicides among 4,487 subjects in the trials; that the trial times were too short at median length of 8 weeks; and that in 10 of the 12 MDD studies, Again, there was no citation of actual suicides associated with SSRIs and no citation of Healy’s work.

Healy reviewed epidemiologic studies that have been cited to exonerate SSRIs. One was analyzed by Healy to show a threefold increase in suicidality compared with other antidepressants.While “treatment-related activation” has been considered primarily with regard to suicidality, it can lead to harm to others as well as to self. Healy summarized data on “hostile episodes” provided by GlaxoSmithKline from placebo-controlled trials with paroxetine in subjects of all ages: 9,219 on paroxetine and 6,455 on placebo. The rubric of “hostility” was used in the trial to code for aggression and violence, including homicide, homicidal acts, and homicidal ideation, as well as aggressive events and “conduct disorders.” No homicides were reported from these trials.

Overall, during both therapy and withdrawal, the RR was 2.1 for hostile events. In children with OCD the RR was 17. Separately, in healthy volunteer studies, hostile events occurred in 3 of 271 subjects on paroxetine vs. none of 138 on placebo. In trials of sertraline on depressed children submitted by Pfizer, 8 of 189 subjects discontinued for aggression, agitation, or hyperkinesis (a coding term for akathisia), compared with 0 of 184 on placebo. In clinical practice, the term akathisia has been restricted to demonstrable motor restlessness, but if that is the only effect, it would have been called dyskinesia according to Healy, who cites four studies linking akathisia to both suicide and homicide.

Actual suicides were combined with suicide attempts in a 2005 meta-analysis of 702 trials of SSRIs vs. either placebo or an active non-SSRI control. Studies were rejected if the citation was a review, a result of duplicate publication, too short, crossover, or had no reporting of actual or attempted suicide. The studies meeting the criteria included 88,000 patients. For attempted suicide, the RR was 2.3 for SSRIs vs. placebo (95% CI, 1.14-4.55). The number needed to treat to harm (sometimes called the “reverse NNT”) was 1 in 684. There was no difference in actual suicide. Of the 702 trials, 104 failed to report adverse events below a certain pre-set limit of 3%, 5%, or 10% of patients. Only 493 trials reported dropout rates, with a mean of 29%, and the mean follow-up time was only 11 weeks. Thus, there was clearly gross underreporting of adverse effects. PDR children and adolescents with an elevated baseline risk of suicide were excluded.

Journal of American Physicians and Surgeons Volume 14 Number 1 Spring 2009 9

More importantly, because actual suicides are involved, Healy cited a study by Donovan et al. that demonstrated a RR=3.4 ( <0.01) for SSRIs compared with all non-SSRI antidepressants involving 222 actual suicides, of which 41 were among patients who had an SSRI within a month of their suicide. Also the British Drug Safety Research Unit recorded more than 110 suicides in 50,000 patients taking an SSRI, an incidence of 219/100,000 compared with 96/100,000 for the non-SSRI mirtazepine (Remeron), an increase of 123/100,000, or 1 in 813 (Table 2). Thus the RR for actual suicide in patients taking SSRIs was 2.3 (or 2.8 for paroxetine). Even here, though, no murders were listed.

In another study cited by Healy, Jick et al. reported 143 actual suicides among 172,598 patients taking antidepressants. The relative risk of suicide in patients taking fluoxetine was 2.1, compared with those taking the tricyclic antidepressant dothiepin. The risk was not age-dependent. SSRI makers keep insisting that there will be more suicides if SSRIs are used as frequently as now. But the RR of 2–3 shown in studies is a number that the number of suicides that may have been prevented, so SSRI use is associated with more suicides, not fewer.

The International Coalition for Drug Awareness in cooperation with the Prozac Survivors Support Group has produced a website on which about 1,600 violent incidents associated with SSRI use are described ( www.ssristories.net ). The first column on the type of incident (murder, school shooting, etc.) is a hot link to a publicly available description of the incident, typically a local newspaper article. A selection of 10 entries (rows) is presented here as Table 3. About 360 suicides are tallied as well as about 400 murder incidents, many of which were multiple murders, each linked to 26 not net includesSSRIs Provide 1,600 Anecdotes of Violence SSRI use (Rosie Meysenburg, personal communication, 2008 .

As the number of “anecdotes” exceeds 1,600—hardly a small number—the association of SSRIs with murder/suicide, often combined, must be taken seriously. The SSRI website was searched to find combined murder/suicide incidents attributed to a specific SSRI. There were three for fluvoxamine, four for citalopram, 10 each for paroxetine and sertraline, and 31 for fluoxetine. Where the studies above substantiated suicide from SSRI use, the total on the SSRI website of 48 simultaneous murder/suicide incidents associated with SSRI use ties together SSRIs and murder. Since there were about two murders per suicide, we may infer that the murder rate on SSRIs could be about 250/100,000. Since no clinical trial involving multiple homicides is ever likely to be run, no firmer evidence is likely to be found. Healy noted that much of the evidence for suicide and murder came from the efforts of journalists and lawyers.
Note that the website carries a prominent warning that “withdrawal can often be more dangerous than continuing on a medication.” Nine violent events cited elsewhere—seven court cases of homicide (one attempted) and two assaults—were associated with specific SSRIs: three with paroxetine, three with sertraline, two with fluoxetine, and one with venlafaxine. Skeptics have cast doubt on whether the prescribed SSRIs were actually taken, especially since many medical records of juveniles were sealed. In the Columbine, Colo., shootings the toxicology report showed “therapeutic” levels of fluvoxamine in one of the shooters. The Red Lake, Minn., shooter had fluoxetine found, according to news items referenced on the website.

A 2004 editorial in by Simon Wessely, M.D., a spokes- man for Eli Lilly, and Robert Kerwin, Ph.D, cited only a single paper by Healy as a source of claims of suicidality that have found a receptive media audience. Tellingly, the only study described at length is by Jick et al. on the correlation of SSRI use and “attempted suicide,” in which the rates on dothiepin, amitriptyline, fluoxetine and paroxetine were not statistically different. Actual suicides in this study (seven on SSRIs) were not mentioned by Wessely and Kerwin, nor were the 143 suicides in Jick’s earlier paper. Jick et al. have been supported partially by GlaxoSmithKline and Pfizer. No study that reported actual suicides on SSRIs was described in detail, let alone refuted. Wessely and Kerwin wrote: “The problem is that depression is unequivocally and substantially associated with suicide and self-harm.” True, but this not the truth.

Table 2. Suicides Related to SSRIs or Mirtazapine

table_02_zoloftbusted1

The legal defense by Lilly, repeated by the media and others, is that any suicides are caused by the condition, depression, not by their drug—whether the violence is associated with short-term drug use, long-term drug use, increased doses, withdrawal, or rechallenge. There is no website, as far as I know, for violent acts committed by persons who never received SSRIs, or for total violent acts; hence the denominator for violent acts is not known. Also unknown is the fraction of potentially violent persons who are treated with SSRIs, or of persons treated with SSRIs who are potentially violent. The published studies on actual suicide, however, compare patients on SSRIs with similar patients on non- SSRI antidepressants or placebo. Children diagnosed with OCD, not depression, also became suicidal on SSRIs, as did healthy volunteers.

Actual two- to threefold increases in suicide rates have been demonstrated as well as they could be. How else could such effects be demonstrated? Who would submit, and what institutional review board or human subjects committee would approve a study explicitly designed to show whether assaultive, homicidal, or other violent behavior increases in subjects prescribed the study drug?

Denial by SSRI makers of culpability for these risks continues to this day. Whether physicians’ acting on the Black Box warnings of 2004 and 2007 for all SSRIs will diminish the incidence of murders and suicides is not yet known. Following the introduction of fluoxetine in 1988, only a year passed before an early user committed multiple murders and suicide; many other examples followed. More than 200 lawsuits have been begun by users of SSRIs and victims’ families charging wrongful death or failure to warn; these have had mixed outcomes. There is now legal precedent for SSRIs as a cause of murder, and the maker of the SSRI is potentially liable for damages, according to David Healy.

Eli Lilly responded with total denial to the lawsuits claiming a link between fluoxetine and violence. Several claims were settled out of court with secret details and no admission of guilt. The Australian David Hawkins was freed from a murder charge by a finding of temporary insanity caused by using sertraline. Tim Tobin of Wyoming won $6.4 million from SmithKline Beecham when a jury found that a murder/suicide committed by Donald Schell was attributable to use of paroxetine. There are four other homicide cases in which the SSRI was deemed to have contributed, resulting in a suspended sentence in one case and an insanity verdict in another.

One case of homicide, with a guilty verdict and a life sentence, followed a judicial ruling that akathisia was associated with SSRI use, but that a causal relationship with homicide could not be argued; thus the link of an SSRI with homicide was disallowed. This was in direct conflict with the findings of the four trials cited above. The SSRI website was searched to find murders related to a specific SSRI whose perpetrators were acquitted based on temporary SSRI-induced insanity. There were two cases with sertraline, four cases with paroxetine, and four cases with fluoxetine. So a precedent has been established for legal recognition that an SSRI can be a cause for murder, and that the drug maker can be found liable for damages. The notices of suicidality for the SSRIs found in the PDR or package inserts before 2004 did not really warn of actual suicide or murder.

200 SSRI-related Lawsuits

The Black Box warning of 2004 about possible suicide in children under 18 years of age did not cover adults or murder at any age, so potential liability for the SSRI makers still exists. In 2007 the warning was extended to persons under age 25 years. David Healy was quoted as saying that the warning was overdue, and that the risk was not likely to disappear above age 25. This was shown by the trials from GlaxoSmithKline on paroxetine cited above.

Antidepressants are extraordinarily difficult to assess for risks or benefits in trials. At most, 11%–30% of patients with depression or related conditions who take SSRIs actually benefited beyond the placebo effect on normal doses. Of the perceived benefit, 32%–67% can be attributed to the placebo effect. Adverse effects, mostly dose-dependent, will appear in up to 75% of patients on normal doses. Of these, studies suggest that suicidality will be observed in an additional 2%–13% (1 in 50 to 1 in 9) of patients on normal doses, beyond what is seen on placebo or many non-SSRI antidepressant drugs. This is sufficiently frequent that a typical prescribing physician should observe examples in routine practice.

The actual suicide rate could be about 123/100,000 (1 in 813) higher in patients on SSRIs than in those on tricyclics or placebo. Studies show that many more suicides are on normal doses of SSRIs beyond what is seen on placebo or many non-SSRI antidepressant drugs. Available data suggest that actual murders may be committed at about the rate of 250/100,000 (1 in 400) SSRI-treated patients beyond what is seen on placebo or many non-SSRI antidepressantdrugs, and that many more murders will be attempted on normal doses as well. While correlation does not prove causation, and results of court trials are not medical science, the data for suicide are solid, and the association of murder with suicide is very suggestive. Now that there is a stronger Black Box warning, physicians who ignore it may be liable for damages; the warning primarily protects the manufacturers of SSRIs. There is obviously great peril in drawing conclusions about causat i on from press report s or court decisions.

While manufacturers have a vested interest in exonerating their drugs, plaintiffs have an interest in blaming it, and defendants in exonerating themselves. We need careful, independent analysis of existing study data. In addition to randomized controlled trials, evidence from basic science ( neuropharmacology) and challenge/dechallenge/rechallenge investigations needs to be sought. Both the public and individual patients are imperiled by an incorrect answer to the pressing questions about these widely prescribed drugs. Future studies may show lower levels of murder and suicide with close supervision, and with better matching of this drug type to patient type.

Conclusionsattemptedsimultaneous
Joel M. Kauffman, Ph.D.

Acknowledgements:
Joel M. Kauffman, Ph.D., professor of chemistry emeritus at the
University of the Sciences, 600 S. 43rd St., Philadelphia, PA 19104-4495,
Contact: kauffman@bee.net.

Learn More
http://www.drugawareness.org/wp-content/uploads/wpsc/product_images/thumbnails/helpicant.jpg
Order Today
Frances E. H. Pane edited the manuscript. David Moncrief piqued my interest by providing a review copy of by Richard DeGrandpre.
The Cult of Pharmacology: How America Became the World’s Most Troubled Drug Culture

Journal of American Physicians and Surgeons Volume 14 Number 1 Spring 2009 11
Potential conflicts of interest: The author has neither a financial interest in any drug mentioned, nor in any alternate treatments for treating any mental illness.

REFERENCES
DeGrandpre R.,Durham, N.C.: Duke University Press; 2006.

The Cult of Pharmacology: How America Became the World’s Most Troubled Drug Culture.
Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment. 2007;297:1683-1696.

Jørgensen AW, Hilden J, Gøtzsche PC. Cochrane reviews compared
with industry supported meta-analyses and other meta-analyses of
the same drugs: systematic review. doi:10.1136/bmj.38973.
444699.0B (publ Oct 2006).

Cohen JS. New York, N.Y.: Tarcher/Putnam; 2001.

Mackay FJ, Dunn NR, Wilton LV, et al. A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies. 1997;6:235-246.

Park L, Covi L. Nonblind placebo trial. 1965;336-345.

Cole JO. Therapeutic efficiency of antidepressant drugs: a review. 1964;190:124-131.

Kirsch I, Moore TJ, Scoboria A, et al. The emperor’s new drugs: an analysis of antidepressant medication data submitted to the U. S. Food and Drug Administration. 2002;5(1):23-33.

Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. 2008;5(2):e45. doi:10.1371/journal.pmed.0050045.

Healy D. One flew over the conflict of interest nest. 2007;6(1):26-27.

Healy D. New York, N.Y.: New York University Press; 2004.

Healy D. FDA Psychopharmacologic Drugs Advisory Committee hearings. Available at:: www.healyprozac.com/PDAC. Accessed May 13, 2007.

Wolfe SM, ed. SSRIs can have dangerous interactions with other drugs. 2008;14(1):2-5. www.citizen.org/hrg/. Accessed Feb 4, 2009.

JAMA BMJ, Over Dose: The Case Against the Drug Companies.
Pharmacoepidemiol Drug Safety Arch Gen Psychiatry

JAMA
Prevention & Treatment
PLoS Medicine
World Psychiatry
Let Them Eat Prozac: The Unhealthy Relationship Between the Pharmaceutical Industry and Depression.
Worst Pills Best Pills News

Braconnier A, Le Coent R, Cohen D. Paroxetine versus clomipramine in adolescents with severe major depression: a double-blind, randomized, multicenter trial. 2003;42:22-29.

Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. 1995;310:1433-1438.

Healy D. Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. 2003:72:71-79.

Healy D, Herxheimer A, Menkes DB. Antidepressants and violence: problems at the interface of medicine and law.
2006;3(9):1478-1487.

Beasley CM, Dornseif BE, Bosomworth JC. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. 1991;303:685-692.

Cohen H. Antidepressants: clinical use and litigation. In: 2nd ed. O’Donnell JT, ed. Tucson, Ariz.: Lawyers & Judges Publ.Co; 2006:379-390.

Ross G. Black Box backfire. Apr 21, 2007.

Donovan S, Clayton A, Beeharry M, et al. Deliberate self-harm and antidepressant drugs. 2000;177:551-556.

Kai zar EE, Gr eenhouse JB, Sel t man H, Kel l eher K . Do antidepressants cause suicidality in children? A Bayesian meta-analysis. 2006;3:73-98.

Berenson ML, Levine DM.. 7th ed. Upper Saddle River, N.J.: Prentilee-Hall; 1998:213-217.

Healy D, Whitaker C. Antidepressants and suicide: risk-benefit conundrums. 2003;28:331-337.

Fergusson D, Doucette S, Glass KC, et al. Association between suicide attempts and selective serotonin reuptake inhibitors.2005;330:396-402.

Donovan S, Kelleher MJ, Lambourn J, Foster T. The occurrence of suicide following the prescription of antidepressant drugs.1999;5:181-192.

Jick SS, Dean AD, Jick H. Antidepressants and suicide.1995;310:215-218.

Wessely S, Kerwin R. Suicide risk and SSRIs. 2004;292:379-381.

Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. 2004;292:338-343.

Carey B. FDA expands suicide warning on drugs. ,May 3, 2007:A17.

J Am Acad Child Psychiatry BMJPsychother PsychosomPLoS Med
BMJ

Drug Injury:Liability, Analysis and Prevention.

Wall Street Journal,Br J Psychiatry Clinical Trials

Basic Business Statistics: Concepts and Applications J Psychiatry Neuroscience

New York Times:Journal of American Physicians and Surgeons Volume 14 Number 1 Spring 2009

USA Trade Name Generic Name:
SSRIs
Celexa
Luvox
Paxil
Prozac
Zoloft
non-SSRIs
Effexor
Remeron
Serzone
Wellbutrin
(UK)
citalopram
fluvoxamine
paroxetine
fluoxetine
sertraline
venlafaxine
mirtazapine
nefazodone
bupropion
dothiepin USA Trade Name Generic Name
SSRIs
Celexa
Luvox
Paxil
Prozac
Zoloft
non-SSRIs
Effexor
Remeron
Serzone
Wellbutrin
(UK)
citalopram
fluvoxamine
paroxetine
fluoxetine
sertraline
venlafaxine
mirtazapine
nefazodone
bupropion
dothiepin

Physicians Desk Reference (PDR)
Joel M. Kauffman, Ph.D.
Table 1. Commonly Prescribed SSRIs and Other Antidepressants Selective Serotonin Reuptake Inhibitor (SSRI) Drugs:
More Risks Than Benefits?

Journal of American Physicians and Surgeons Volume 14 Number 1 Spring 2009 7 Physicians Desk Reference (PDR)
Joel M. Kauffman, Ph.D.
Table 1. Commonly Prescribed SSRIs and Other Antidepressants Selective Serotonin Reuptake Inhibitor (SSRI) Drugs:
More Risks Than Benefits?

Journal of American Physicians and Surgeons Volume 14 Number 1 Spring 2009 7

JAMAwhole12,69210,98313,74112,73450,15013,554

10 dead, 7 wounded: dosage increased one week before rampage
15 year old shoots two teachers, killing one: then kills himself
Columbine High School: 15 dead, 24 wounded
Four dead, twenty injured after Prozac withdrawal
Teen shoots at two students: kills his father
Jury finds Paxil was cause of murder-suicide
Man cleared of charges due to Paxil withdrawal defense
Not guilty by reason of Prozac induced insanity: mother kills daughter
Nine dead, 12 wounded in workplace shooting
11 year old hangs himself: lawsuit

Journal of American Physicians and Surgeons Volume 14 Number 1 Spring 2009

2,190 total views, 3 views today

Matt Miller – Zoloft (1 week!) – induced suicide

http://www.antidepressantsfacts.com/Matt-Miller.htm

By Anne McIlroy
As written in The Globe and Mail (www.globeandmail.com)

When Matt Miller’s family moved to a bigger house in a new neighbourhood in Kansas City, Mo., the athletic 13-year-old with thick blond hair found that he couldn’t penetrate the cliques at his new school. He was a nobody, an outsider.

“He was angry at us, he was angry at the school, his grades suffered. He wasn’t himself,” said his father, Mark Miller.

The boy’s teachers recommended that he see a psychiatrist, who prescribed Zoloft, an antidepressant in the same chemical family as Prozac. The doctor said it would help Matt’s mood, make him feel better about himself. The boy started taking the pills and seemed to be in good spirits for a few days.

But then he began showing signs of intense nervousness and agitation. He couldn’t sit still, his father remembers. He kept kicking people under the table. His eyes were sunken and he couldn’t sleep, yet he had a restless energy.

After six days on the drug, on July 28, 1997, Matt hanged himself in his bedroom closet.

“Suicide always takes you by surprise, but no one could have imagined that Matt would have done that,” Miller said in an interview. “There was no previous attempt, no serious threat of it, no note, no premeditation. “It was a very impulsive act I am convinced was brought about by the stimulant nature of the drug.”

Miller has launched a lawsuit against Pfizer Inc., which makes Zoloft. He is one of about 200 people who have sued — so far unsuccessfully — the makers of Prozac and similar products. The plaintiffs contend that the drugs, known as selective serotonin reuptake inhibitors, caused their loved ones to kill themselves and, in some cases, hurt or kill others as well. One of the few cases to go to trial so far was that of William Forsyth, a 63-year-old wealthy Hawaii businessman who stabbed to death his wife of 37 years and then killed himself in 1993. At the time, he had been taking Prozac for 11 days for panic attacks.

In 1999, a jury in the civil lawsuit cleared Prozac of liability in the deaths. Forsyth’s adult children began another suit last year accusing Eli Lilly and Co., the maker of the drug, of covering up damaging details about the antidepressant.

Chief among the scientific experts who have given people, including Miller and Forsyth’s children, reason to believe that a link may exist between antidepressants and suicide is Dr. David Healy, whom Miller has engaged as an expert witness in his suit.

Healy is a well-known British psychiatrist who argues that Prozac and similar drugs may trigger suicide in some patients, and that there should be warning labels on the products.

To Miller, Healy is a hero, a crusading scientist with the guts and credibility to challenge the powerful, multinational drug companies in an era in which many researchers and institutions depend on them for funding. But discussing the down side of Prozac does not appear to have been a good career move. Healy’s blunt expression of his views may have cost him a job at the Centre for Addiction and Mental Health, a teaching hospital associated with the University of Toronto. The centre had been recruiting him for months, but last year rescinded his written job offer after he gave a speech warning that Prozac may trigger suicide in some patients.

Eli Lilly Canada Inc. is a major corporate donor to the centre, but university and hospital officials say their decision had nothing to do with wanting to please the drug company or to avoid damaging future fundraising efforts. They say their reasons are confidential. Healy says the only explanation he was offered was that his lecture “solidified” the view that he was not a good fit.

For Eli Lilly’s part, it points out that a U.S. Food and Drug Administration panel of experts voted six to three against requiring Prozac to carry a suicide-risk warning label. In September of 1991, the FDA concluded that there was no credible evidence of a causal link between the use of antidepressant drugs, including Prozac, and suicides or violent behaviour. And a paper published in March of 1991 by Jerrold Rosenbaum of Massachusetts General Hospital found that patients on Prozac were not prone to suicide any more than patients on other medication.

Eli Lilly said, in a written response to questions from The Globe and Mail: “There is, to the contrary, published scientific evidence showing that Prozac and medicines like it actually protect against such behaviour — reducing aggressive and suicidal thoughts and behaviour.”

When Prozac was introduced in the late 1980s, it was billed as a wonder drug that could combat depression with far fewer risks than previous medications, including the danger of an overdose or problems when mixed with alcohol. Prozac and drugs like it — Zoloft, Paxil and Luvox — were said to help with emotional limitations such as low self-esteem and fear of rejection. Prozac was a commercial as well as a medical miracle, sold to an estimated 40 million people worldwide since it hit the market.

The drug boosts levels of the neurotransmitter serotonin, which seems to improve the mood of patients. But within a few years of Prozac’s launch came hints that it brought out a dark side in a small fraction of users. Martin Teicher, a researcher at Harvard University, published an article in the American Journal of Psychiatry in 1990 that discussed six cases in which patients became intensely preoccupied with suicide after taking the drug. Other scientists also found a potential link between Prozac and suicide.

Healy says in one of his published papers that Eli Lilly scientists collaborated with the FDA on designing an experiment that would measure how serious the problem was, but they then decided against conducting it. Instead, in 1991, Eli Lilly published an analysis of data taken from existing trials. Its conclusion? There was no increase of suicidal thoughts or suicide among depressed patients taking Prozac.

But Healy says in the paper that data from only about one-eighth of the patients in the clinical trials were included. No mention was made that some had been prescribed a sedative that may have alleviated an intense nervous state that can lead to suicide, which is called akathisia, he says. The analysis also did not point out that 5 per cent of patients dropped out of the studies because they were anxious and agitated and may have been suffering from akathisia, Healy says.

Another document, dated Nov. 13, 1990, shows that company scientists were pressured by executives to soften physicians’ reports of suicidal thoughts or suicide attempts, according to Harvard psychiatrist Joseph Glenmullen, who obtained the document and is author of the book Prozac Backlash. Additional evidence about the potential risks can be found in the patent for a second-generation Prozac pill, which Eli Lilly has licensed. The patent says the new and improved Prozac would decrease side effects including: “nervousness, anxiety, and insomnia,” as well as “inner restlessness (akathisia), suicidal thoughts and self-mutilation.”

But at the same time, Eli Lilly says these symptoms are not associated in any significant way with taking the current version of Prozac. The new Prozac — which incidentally was co-developed by Teicher, one of the drug’s early critics — isn’t yet on the market, Last year, Healy published a study in the journal Primary Care Psychiatry that said two of 20 healthy volunteers taking an antidepressant in the same family as Prozac reported feeling suicidal.

But by his calculations, probably 40,000 people have committed suicide while on Prozac since its launch, above and beyond the number who would have taken their own lives if their condition had been left untreated.

The German government now requires warning labels, and Britain is considering them. Canada and the United States do not. Healy says he is not opposed to Prozac and thinks that it can do a lot of good. But he says it is unethical and irresponsible not to warn doctors about the potential dangers, and believes Eli Lilly chose not to do so to maximize profits.

He says family doctors seem to be increasingly prescribing Prozac and other antidepressants to children and now to women complaining of severe premenstrual symptoms, yet patients in North America do not have to be told about the potential risks.

Eli Lilly and the other drug companies argue that depression, not antidepressants, are to blame for suicides. Pfizer is trying to have Healy barred from testifying in the Miller case, questioning his credibility as an expert witness.

So what are Canadian consumers to think? Jacques Bradwejn, chairman of the psychiatry department at the University of Ottawa, says he has reviewed the literature and agrees with the FDA and Eli Lilly that there is no evidence that Prozac and similar drugs cause more suicides than would have occurred if patients had not been treated.

But a small number of patients — even as many as 1 per cent — may fall into a nervous state that could trigger suicide, he said, adding that more research is needed to better understand the problem.

While Prozac may be overprescribed for patients who are not truly ill, Bradwejn worries that the message that the Prozac is dangerous will do more harm than good for those who are moderately to severely depressed. “If the message is too alarmist, it could have a very negative effect on Canadians.”

DEPTHS OF DESPAIR

A study by Dr. David Healy found that two of 20 healthy volunteers taking a selective serotonin reuptake inhibitor in the same family as Prozac reported suicidal feelings. This is the story of one of those people, a 30-year-old woman who didn’t know what drug she was taking, as recorded in the study. “On the Friday she telephoned early in the morning, distressed and tearful from the previous night. Her conversation was garbled. She described almost going out and killing herself. . .

“The night previously she had felt complete blackness all around her. . . . She felt hopeless and alone. It seemed that all she could do was to follow a thought that had been planted in her brain by some alien force. “She suddenly decided she should go and throw herself in front of a car, that this was the only answer. It was as if there was nothing out there apart from the car. . . . She didn’t think of her partner or child. She was walking out the door when the phone went. This stopped the tunnel of suicidal ideation.

“She later became distraught at what she had nearly done and guilty that she had not thought of her family.”

790 total views, 6 views today